Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CGEM

Cullinan Therapeutics Inc

Dec 20 • 04:00PM ET

11.60

Dollar change +0.65
Percentage change 5.94	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD INCY JAZZ NVAX KURA EXEL BPMC KPTI ESPR ONCY

| Held by: VTI IWM XBI VXF IWO VTWO IBB SCHA VHT DFAT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.88	Insider Own	36.20%	Shs Outstand	58.14M	Perf Week	-1.28%
Market Cap	715.53M	Forward P/E	-	EPS next Y	-3.17	Insider Trans	-0.18%	Shs Float	37.15M	Perf Month	-7.79%
Income	-143.54M	PEG	-	EPS next Q	-0.79	Inst Own	77.32%	Short Float	24.65%	Perf Quarter	-30.25%
Sales	0.00M	P/S	-	EPS this Y	17.66%	Inst Trans	5.79%	Short Ratio	16.99	Perf Half Y	-33.22%
Book/sh	10.80	P/B	1.07	EPS next Y	-4.18%	ROA	-25.01%	Short Interest	9.16M	Perf Year	32.72%
Cash/sh	9.37	P/C	1.24	EPS next 5Y	-	ROE	-26.18%	52W Range	8.49 - 30.19	Perf YTD	13.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-62.42%	ROI	-22.82%	52W High	-61.57%	Beta	-0.10
Dividend TTM	-	Quick Ratio	24.46	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	36.63%	ATR (14)	0.78
Dividend Ex-Date	-	Current Ratio	24.46	EPS Y/Y TTM	22.90%	Oper. Margin	-	RSI (14)	38.05	Volatility	7.37% 5.88%
Employees	85	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	32.67
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	24.17%	Payout	-	Rel Volume	1.60	Prev Close	10.95
Sales Surprise	-	EPS Surprise	12.43%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	539.08K	Price	11.60
SMA20	-6.13%	SMA50	-19.15%	SMA200	-35.02%	Trades		Volume	862,713	Change	5.94%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-24-24	Initiated	UBS	Buy	$30
May-01-24	Initiated	Stifel	Buy	$40
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform	$30
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy	$20
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40
Feb-02-21	Initiated	SVB Leerink	Outperform	$52
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight	$38
Feb-02-21	Initiated	Evercore ISI	Outperform	$55
Feb-01-21	Initiated	H.C. Wainwright	Buy	$47

Show Previous Ratings

Nov-14-24 10:01AM	Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 (GlobeNewswire)
Nov-07-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.46%
Nov-05-24 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-04-24 07:00AM	Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 (GlobeNewswire)
Oct-16-24 07:00AM	Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus (GlobeNewswire) +8.44%
07:00AM	Loading…
Sep-17-24 07:00AM	Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus (GlobeNewswire)
Sep-16-24 07:00AM	Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus (GlobeNewswire) -5.68%
Sep-14-24 04:15AM	Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-03-24 06:26AM	Cullinan Therapeutics announces success for zipalertinib as combo therapy (Clinical Trials Arena)
Jun-01-24 07:00AM	Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib (GlobeNewswire)
May-24-24 08:00AM	Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire) +6.53%
May-23-24 05:04PM	Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 (GlobeNewswire)
May-16-24 12:03PM	HC Wainwright Adjusts Price Target on Cullinan Oncology to $28 From $29, Maintains Buy Rating (MT Newswires) -10.89%
10:54PM	Loading…
May-15-24 10:54PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 03:09AM	Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ... (GuruFocus.com)
May-01-24 07:05AM	Stifel Initiates Cullinan Oncology With Buy Rating, $40 Price Target (MT Newswires)
Apr-29-24 07:00AM	Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer (GlobeNewswire) +7.19%
Apr-24-24 04:29PM	Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? (Benzinga) +13.32%
10:09AM	Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024 (GlobeNewswire)
Apr-16-24 03:32PM	Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity (Benzinga)
07:00AM	Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases (GlobeNewswire)
06:59AM	Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement (GlobeNewswire)
04:48AM	Cullinan changes name, pivots to autoimmune disease (BioPharma Dive)
Mar-16-24 05:31AM	Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
Mar-14-24 12:53PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-01-24 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
08:00AM	Loading…
Feb-27-24 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-02-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-30-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-24-24 07:02PM	Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares (GuruFocus.com)
Dec-18-23 04:53PM	Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.80%
Dec-14-23 04:30PM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines (GlobeNewswire)
Nov-08-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 12:01PM	Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023 (GlobeNewswire) +5.53%
Oct-30-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-06-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 07:00AM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (GlobeNewswire)
Aug-03-23 04:15PM	REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations (PR Newswire)
Jul-31-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-09-23 04:07PM	Why Shares of Cullinan Oncology Jumped This Week (Motley Fool)
May-25-23 05:00PM	Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023 (GlobeNewswire) +5.13%
May-11-23 04:01PM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-26-23 10:08AM	Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023 (GlobeNewswire)
Apr-20-23 07:00AM	Cullinan Oncology to Participate in Stifels 2023 Targeted Oncology Days (GlobeNewswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-27-23 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines (GlobeNewswire)
Mar-14-23 04:35PM	Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-09-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 08:00AM	Cullinan Oncology to Participate in Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-13-23 07:00PM	Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed (GlobeNewswire)
Feb-02-23 04:01PM	Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-01-23 04:42PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-24-23 08:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (GlobeNewswire) +5.53%
Jan-23-23 11:07AM	12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds (Insider Monkey)
Jan-03-23 05:13PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-28-22 10:31PM	11 Cheap Value Stocks to Buy According to Seth Klarman (Insider Monkey)
Dec-02-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-22 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 08:00AM	Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors (GlobeNewswire)
Nov-01-22 05:23PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-25-22 07:00AM	Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619 (GlobeNewswire) +6.03%
Oct-03-22 04:50PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-22 08:00AM	Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference (GlobeNewswire) +5.36%
Sep-01-22 05:27PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-22 04:57PM	Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer (GlobeNewswire)
Aug-10-22 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-01-22 04:55PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.24%
08:00AM	Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference (GlobeNewswire)
Jul-29-22 05:00AM	Why are Massachusetts CEOs paid so much money? Here's a primer (American City Business Journals)
05:00AM	Best bang for the buck: Which CEOs are a bargain for shareholders? (American City Business Journals)
Jul-05-22 04:01PM	Cullinan Oncology to Participate in William Blair Biotech Focus Conference (GlobeNewswire)
Jul-01-22 04:37PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-23-22 08:00AM	Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 (GlobeNewswire)
Jun-01-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.08%
May-31-22 08:00AM	Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting (GlobeNewswire) -6.88%
May-26-22 08:45AM	Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting (GlobeNewswire)
May-19-22 08:00AM	Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) -5.01%
May-16-22 06:45AM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-12-22 11:18AM	Why Are Cullinan Oncology Shares Rising Today? (Benzinga) +23.12%
02:00AM	Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taihos Acquisition of Cullinan Pearl (GlobeNewswire)
May-08-22 09:23AM	Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth (Simply Wall St.)
May-02-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.34%
Apr-27-22 10:00AM	Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting (GlobeNewswire)
Apr-05-22 08:00AM	Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire)
Apr-04-22 04:34PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.55%
Mar-29-22 07:54AM	Cullinan Oncology Lead Cancer Program Shows Confirmed ORR Of 41% In Lung Cancer Setting (Benzinga)
Mar-28-22 04:01PM	Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients (GlobeNewswire)
Mar-17-22 07:08AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
07:00AM	Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022 (GlobeNewswire)
Mar-09-22 08:00AM	Cullinan Oncology to Present at the Barclays Global Healthcare Conference (GlobeNewswire) +8.91%
Mar-08-22 05:30PM	Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022 (GlobeNewswire)
Feb-28-22 08:00AM	Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors (GlobeNewswire)
Feb-12-22 06:50AM	Investors in Cullinan Oncology (NASDAQ:CGEM) have unfortunately lost 66% over the last year (Simply Wall St.)

Cullinan Therapeutics, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Michaelson Jennifer	Chief Scientific Officer	Dec 18 '24	Sale	11.41	4,693	53,547	99,760	Dec 20 05:00 PM
Jones Jeffrey Alan	Chief Medical Officer	Dec 18 '24	Sale	11.41	4,632	52,851	114,059	Dec 20 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Dec 18 '24	Sale	11.41	3,482	39,730	90,651	Dec 20 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 12 '24	Sale	12.52	3,489	43,682	104,453	Dec 16 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Nov 05 '24	Sale	15.64	8,000	125,120	107,942	Nov 07 05:30 PM
Michaelson Jennifer	Chief Scientific Officer	Sep 05 '24	Sale	18.09	8,000	144,720	115,942	Sep 09 05:30 PM
JENNIFER MICHAELSON & MARC D M	Officer	Sep 05 '24	Proposed Sale	18.68	16,000	298,880		Sep 05 04:27 PM
Michaelson Jennifer	Chief Scientific Officer	Jul 05 '24	Sale	16.33	8,000	130,640	123,942	Jul 09 05:30 PM
Ebeling Thomas	Director	Jun 10 '24	Option Exercise	13.00	18,450	239,850	186,653	Jun 11 06:00 PM
Michaelson Jennifer	Chief Scientific Officer	May 06 '24	Option Exercise	4.30	50,000	215,000	187,582	May 08 07:30 PM
Michaelson Jennifer	Chief Scientific Officer	May 07 '24	Option Exercise	4.30	5,606	24,106	135,188	May 08 07:30 PM
Michaelson Jennifer	Chief Scientific Officer	May 06 '24	Sale	28.07	58,000	1,628,159	129,582	May 08 07:30 PM
Michaelson Jennifer	Chief Scientific Officer	May 07 '24	Sale	30.06	5,606	168,516	129,582	May 08 07:30 PM
Savill Corrine	Chief Business Officer	Feb 01 '24	Option Exercise	4.30	40,000	172,000	205,990	Feb 02 09:35 PM
Savill Corrine	Chief Business Officer	Feb 01 '24	Sale	16.18	40,000	647,200	165,990	Feb 02 09:35 PM
Savill Corrine	Chief Business Officer	Jan 29 '24	Option Exercise	4.30	40,000	172,000	205,990	Jan 30 07:00 PM
Savill Corrine	Chief Business Officer	Jan 29 '24	Sale	14.09	40,000	563,600	165,990	Jan 30 07:00 PM
Savill Corrine	Chief Business Officer	Jan 23 '24	Option Exercise	4.30	21,316	91,659	187,306	Jan 24 05:00 PM
Savill Corrine	Chief Business Officer	Jan 22 '24	Option Exercise	4.30	14,559	62,604	184,674	Jan 24 05:00 PM
Savill Corrine	Chief Business Officer	Jan 23 '24	Sale	12.46	21,316	265,597	165,990	Jan 24 05:00 PM
Savill Corrine	Chief Business Officer	Jan 22 '24	Sale	12.14	18,684	226,911	165,990	Jan 24 05:00 PM
AHMED NADIM	President and CEO	Dec 26 '23	Sale	9.24	4,272	39,473	111,550	Dec 27 06:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGEM

Cullinan Therapeutics Inc

Upgrade your FINVIZ experience